Trial Profile

A Pivotal, Registration Study to Evaluate SLS-006 for the Treatment of Parkinson's Disease

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 31 Jan 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aplindore (Primary)
Indications Parkinson's disease
Focus Registrational; Therapeutic Use
Sponsors Seelos Therapeutics

Most Recent Events

31 Jan 2019 New trial record
24 Jan 2019 According to a Seelos Therapeutics media release, the company intends to meet with the FDA and the European Medicines Authority (EMA) to discuss the plans for this pivotal registration study to commence in 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com